Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Dominic J. Vitello

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4163-7759; OpenAlex author ID A5032770196. Sources: OpenAlex.

Their work

Papers
12 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 4 papers · 2026: 6 papers

Papers 12

  1. Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/jso.70296↗
  2. Quantitative KRAS mutational burden by next-generation sequencing predicts outcomes in localized pancreatic cancer Co-author DOI 10.1016/j.surg.2026.110303↗
  3. Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer Patients Treated With Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000006562↗
  4. High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-26-0609↗
  5. KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer. First author DOI 10.1245/s10434-026-20447-0↗
  6. ASO Visual Abstract: KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer First author DOI 10.1245/s10434-026-20549-9↗
  7. The Current Role of Circulating Tumor DNA in the Management of Pancreatic Cancer. First author DOI 10.1007/s12029-024-01129-0↗
  8. A comparison of outcomes for patients with localized pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy with and without radiation prior to cu… Co-author DOI 10.21037/cco-25-60↗
  9. Translating the multifaceted use of liquid biopsy to management of early disease in pancreatic adenocarcinoma. First author DOI 10.3389/fonc.2025.1520717↗
  10. Ultra-sensitive detection of mutant KRAS in circulating tumor DNA predicts survival in resectable pancreatic adenocarcinoma. Co-author DOI 10.3389/fonc.2025.1657746↗
  11. Modern Treatment Strategies for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1007/978-3-031-61238-1_4↗
  12. A review of response in neoadjuvant therapy for exocrine pancreatic cancer. Co-author DOI 10.1002/jso.26369↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akhil Chawla · 10 shared papers, 2025–2026 · strength 2.86
  2. M.C. Cox · 9 shared papers, 2025–2026 · strength 2.56
  3. David J. Bentrem · 7 shared papers, 2021–2026 · strength 1.76
  4. Alex Horowitz · 5 shared papers, 2026 · strength 1.25
  5. Krishay Sridalla · 5 shared papers, 2026 · strength 1.25
  6. Dhavan Shah · 3 shared papers, 2026 · strength 0.70
  7. Marina Talamonti · 1 shared paper, 2024 · strength 0.46
  8. Cade F. Bennett · 1 shared paper, 2025 · strength 0.30
  9. Ishan Roy · 1 shared paper, 2026 · strength 0.29
  10. Chengwei Peng · 1 shared paper, 2025 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.